+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07135895

Evaluation of the Artix Thrombectomy System for Treatment of Acute Lower Limb Arterial Occlusions Using a Single-Arm Post-Market Study

Led by Inari Medical · Updated on 2026-10-13

250

Participants Needed

23

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of the Artix Thrombectomy System, a device designed for removing arterial blockages in the lower limbs. This study focuses on patients with acute lower limb arterial occlusions occurring below the inguinal ligament, with symptoms lasting 14 days or less. The trial is a post-market, prospective, multicenter, single-arm study sponsored by Inari Medical that aims to gather important data on this treatment approach. Participants receive treatment using the Artix Thrombectomy System to non-surgically remove arterial emboli and thrombi from the lower extremities. This device is used on target lesions in native vessels sized between 3 mm and 8 mm, classified under Rutherford categories I, IIa, or IIb. The study monitors immediate effectiveness after the procedure and safety within 48 hours, with no comparison to other treatments. During the study, participants undergo assessments immediately following treatment and at follow-up visits up to one month later. Researchers will evaluate outcomes such as distal embolization serious adverse events during the procedure, all-cause mortality, limb salvage, and amputation-free survival at one month. Participants are monitored closely to understand the devices performance and safety over the study period, which lasts until October 2029.

CONDITIONS

Brief Title

The ArtixASCEND Study

Research Team

J

James Allen

C

Chris Ottaviano

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here